Patent application number | Description | Published |
20150131512 | ADAPTIVE MODULATION IN A HYBRID VEHICLE COMMUNICATION SYSTEM - Techniques for providing hybrid communications to devices on vehicles include using a selected modulation scheme on a forward link to deliver data (that is intended to be received by an on-board device) onto a vehicle, and using a reverse link in a different frequency band to send reverse data from the vehicle. Based on the reverse data, a subsequent pre-defined modulation scheme for a subsequent forward transmission is selected from a plurality of modulation schemes corresponding to a plurality of performance levels of data delivery. The selections may be based on a current geo-spatial location of the vehicle, a type of data, and/or on one or more other dynamic conditions. The forward data may be multiplexed and/or multicast. Thus, adaptive modulation is achieved in a hybrid communications system in which the forward link and the reverse link to the vehicle are supported by different wireless communication bands. | 05-14-2015 |
20150131513 | HYBRID COMMUNICATIONS FOR DEVICES ON VEHICLES - Techniques for providing hybrid communications to devices on vehicles include using a forward link to deliver data, that is intended to be received by an on-board device, onto a vehicle, and using a reverse link in a different frequency band to send reverse data from the vehicle. A subsequent forward link is selected, based on the reverse data, from a plurality of forward links, each of which is supported by a different frequency band. Forward data may be multiplexed and/or multicast, and in some cases, multiple forward links may be used for distributed forward data delivery. These techniques allow for efficient data delivery to the vehicle, and in particular while the vehicle is in transit and link conditions are dynamic. | 05-14-2015 |
20150131514 | OPTIMIZING USAGE OF MODEMS FOR DATA DELIVERY TO DEVICES ON VEHICLES - Techniques for optimizing modem use for data delivery to vehicles that are near to or parked at ports include using a high-capacity forward communications link, in a first frequency band, to support a logical forward link of a data tunnel via which data is delivered between a data provider and the vehicle. Instead of using the reverse communications link of the first frequency band, though, a reverse communications link in a different frequency band is used to support the reverse logical link of the data tunnel, as reverse data typically requires less bandwidth. Thus, the forward communications link is used in a high-throughput, unidirectional manner. Forward data may be multiplexed and/or multicast, and in some cases, multiple forward communications links may be used in parallel to support the logical forward link of the data tunnel. | 05-14-2015 |
20150318913 | DATA DELIVERY TO DEVICES ON VEHICLES USING MULTIPLE FORWARD LINKS - Data content that is to be utilized, as a whole, at a target device on-board a vehicle is apportioned for delivery onto the vehicle via multiple forward links, each of which is included in a different frequency band and/or used a different protocol. A mapping or selection of a specific portion of the data content for a specific forward link may based on a data content type of the specific portion, as well as on other dynamic or static criteria. The target device may operate on the subsets of the data content as it receives each subset. Thus, time critical/foundational portions of the data content may be delivered using a faster forward link, larger elements of the data content may be delivered using a higher-bandwidth forward link, and/or portions of the data content requiring a higher degree of accuracy may be delivered using a more robust forward link, for example. | 11-05-2015 |
Patent application number | Description | Published |
20140341957 | Surfactant Responsive Dispersion Polymerized Micro-Gels - A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in the presence of a surfactant is disclosed. The crosslinked, nonionic amphiphilic polymer is prepared by dispersion polymerization in the presence of a stabilizing polymer. The yield stress fluid is capable of suspending insoluble materials in the form of particulates and/or droplets requiring suspension or stabilization. | 11-20-2014 |
20140348887 | Surfactant Responsive Emulsion Polymerized Micro-Gels - A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in the presence of a surfactant is disclosed. The yield stress fluid is capable of suspending insoluble materials in the form of particulates and/or droplets requiring suspension or stabilization. | 11-27-2014 |
20140364511 | Surfactant Responsive Micro-Gels - A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in the presence of a surfactant is disclosed. The yield stress fluid is capable of suspending insoluble materials in the form of particulates and/or droplets requiring suspension or stabilization. | 12-11-2014 |
20150335565 | IRRITATION MITIGATING POLYMERS AND USES THEREFOR - The present invention provides mild cleansing and cleaning compositions and methods for mitigating irritation induced by harsh detersive surfactants contained therein. The invention relates to a method of reducing skin irritation associated with a cleansing composition comprising at least one surfactant, the method comprising combining an effective amount of at least one nonionic amphiphilic polymer with at least one detersive surfactant selected from anionic surfactants, amphoteric surfactants, nonionic surfactants and combinations of two or more thereof. The at least one nonionic amphiphilic irritation mitigating polymer is prepared from a free radically polymerizable monomer composition comprising at least one hydrophilic monomer and at least one hydrophobic monomer. | 11-26-2015 |
20150342860 | IRRITATION MITIGATING POLYMERS AND USES THEREFOR - The present invention provides mild cleansing and cleaning compositions and methods for mitigating irritation induced by harsh detersive surfactants. The invention relates to a method of reducing skin irritation associated with a cleansing composition comprising at least one surfactant, the method comprising combining an effective amount of at least one nonionic amphiphilic polymer with at least one detersive surfactant selected from anionic surfactants, amphoteric surfactants, nonionic surfactants and combinations of two or more thereof. The at least one nonionic amphiphilic irritation mitigating polymer is prepared from a free radically polymerizable monomer composition comprising at least one hydrophilic monomer and at least one hydrophobic monomer, wherein said N-vinyl lactam and wherein said hydrophobic monomer is selected from a vinyl ester of a C | 12-03-2015 |
20160022566 | IMPROVED FOAMING PERFORMANCE IN CLEANSING COMPOSITIONS THROUGH THE USE OF NONIONIC, AMPHIPHILIC POLYMERS - The invention relates to a method for improving the foaming and/or yield value properties associated with surfactant containing compositions comprising at least one anionic surfactant, the method comprises combining an effective amount of at least one nonionic, amphiphilic polymer with at least one anionic detersive surfactant in combination with an optional surfactant selected from amphoteric surfactants, nonionic surfactants and combinations of two or more thereof. The at least one nonionic amphiphilic polymer is prepared from a free radically polymerizable monomer composition comprising at least one hydrophilic monomer and at least one hydrophobic monomer, wherein said hydrophilic monomer is selected from a N-vinyl lactam and wherein said hydrophobic monomer is selected from a vinyl ester of a C | 01-28-2016 |
Patent application number | Description | Published |
20130330348 | ANTI-NGF ANTIBODIES AND THEIR USE - The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental. | 12-12-2013 |
20140178389 | IL-1 BINDING PROTEINS - The disclosure provides binding proteins that specifically bind to IL-1α and IL-1β. These binding proteins can be organized into DVD-Igs. These proteins can be used to modulate the activity of IL-1α and/or IL-1β and can be used for the treatment immunological diseases such as rheumatoid arthritis, osteoarthritis, psoriasis, multiple sclerosis, and other autoimmune diseases. In addition, their uses in the amelioration and/or treatment of pain in an individual suffering from a disease or disorder associated with IL-1 accumulation. | 06-26-2014 |
20160002324 | ANTI-NGF ANTIBODIES AND THEIR USE - The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental. | 01-07-2016 |
Patent application number | Description | Published |
20110256135 | ANTI-NERVE GROWTH FACTOR (NGF) ANTIBODY COMPOSITIONS - The present invention relates to stable compositions of anti-NGF antibodies, and antigen-binding fragments thereof, and their uses in the prevention and/or treatment of various diseases and disorders in which NGF activity is detrimental, e.g., pain disorders. | 10-20-2011 |
20140134172 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 05-15-2014 |
20140161817 | STABLE DUAL VARIABLE DOMAIN IMMUNOGLOBULIN PROTEIN FORMULATIONS - The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein. The invention also provides stable lyophilized formulations comprising a Lyophilized Stable Dual Variable Domain Immunoglobulin (LS-DVD-Ig) protein. | 06-12-2014 |
20140348835 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMUNOGLOBULIN AND USES THEREOF - Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity. | 11-27-2014 |
Patent application number | Description | Published |
20090292211 | Methods and Apparatus for Optical Spectroscopic Detection of Cell and Tissue Death - A method for detecting death process of a cell or tissue of a living subject. In one embodiment, the method includes the steps of illuminating the cell or tissue of the living subject with a coherent light, collecting fluorescent light returned from the illuminated cell or tissue of the living subject, identifying a NAD(P)H peak of a spectrum of the collected fluorescent light with a wavelength, λ | 11-26-2009 |
20110295125 | Apparatus and method for radio frequency ablation of a liver tumor in liver tissues - A method for detecting death process of a cell or tissue of a living subject. In one embodiment, the method includes the steps of illuminating the cell or tissue of the living subject with a coherent light, collecting fluorescent light returned from the illuminated cell or tissue of the living subject, identifying a NAD(P)H peak of a spectrum of the collected fluorescent light with a wavelength, λ | 12-01-2011 |
20140372138 | INTERMEDIATE CHECK POINTS IN MEDICAL CARE LINES FOR AUTOMATICALLY IDENTIFYING CARE DEFICIENCIES - A quality of medical care can be estimated based on factors such as a mortality rate or complications rate. However, by this point, poor care may have already reached its consequence. In some embodiments, characteristics pertaining to a care experience are analyzed to identify those predictive of a health result. The identified characteristics may include ones that depend on care factors, such that they are not, alone, easy to manipulate. Those characteristics can then be monitored, and unsatisfactory characteristics can be addressed. | 12-18-2014 |
Patent application number | Description | Published |
20090274713 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 11-05-2009 |
20100092495 | POTENT CELL-BINDING AGENT DRUG CONJUGATES - The present invention relates to the use of about 2 to about 8 drug molecules, for example, maytansinoid, per cell binding agent, such as an antibody, and maximal efficacy as compared to a drug load of lesser or higher number of drugs linked to such a cell binding agent. | 04-15-2010 |
20110003969 | CONJUGATION METHODS - This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues | 01-06-2011 |
20110280890 | PRODRUGS OF CC-1065 ANALOGS - The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody, and for the therapeutic use of such prodrug and conjugates, and for processes for preparing such prodrugs and conjugates. | 11-17-2011 |
20110281856 | METHOD OF TARGETING SPECIFIC CELL POPULATIONS USING CELL-BINDING AGENT MAYTANSINOID CONJUGATES LINKED VIA A NON-CLEAVABLE LINKER, SAID CONJUGATES AND METHODS OF MAKING SAID CONJUGATES - The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population. | 11-17-2011 |
20140179906 | CONJUGATION METHODS - This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues | 06-26-2014 |
Patent application number | Description | Published |
20080298600 | AUTOMATED REAL SPEECH HEARING INSTRUMENT ADJUSTMENT SYSTEM - A method for fitting a hearing instrument comprises placing the hearing instrument in situ includes receiving an audiogram of the user, determining a target gain for the hearing instrument as a function of the audiogram, exposing a reference sensor located adjacent the hearing instrument to an external speech signal, measuring an external sound pressure level (SPL) via the reference sensor, exposing a probe sensor coupled to the inside of the ear to the output of the hearing instrument while the hearing instrument is in situ, measuring an internal sound pressure level (“SPL”) inside the ear of the user via the probe sensor, determining an offset gain as a function of the external SPL, the target gain and the internal SPL, and automatically adjusting a gain of the hearing instrument according to the offset gain. A system for automatically fitting a hearing impaired person with a digital hearing aid in situ includes a digital hearing aid, a reference volume sensor, a probe sensor, a sound mapping module and a parameter control module. | 12-04-2008 |
20120140937 | Automated real speech hearing instrument adjustment system - A method for adjusting a hearing instrument to reduce feedback by placing a hearing instrument having an adjustable frequency response in a wearer's ear, providing a probe microphone for measuring the sound pressure level inside the ear and a reference microphone for measuring the sound pressure level outside the ear, exposing the ear to a stimulus and a dynamic event, determining the gain as a function of frequency from the difference in sound pressure level measured by the probe microphone and the reference microphone, identifying a feedback peak where the frequency is in the center of a range of frequencies and corresponds to the maximum gain in that range of frequencies and adjusting the hearing instrument to reduce the gain at a frequency corresponding to the frequency of the feedback peak. | 06-07-2012 |